A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Clinical trial NCT05290597 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05290597
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-22
- Primary completion
- 2026-01-28
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.